Turmoil stemming from the novel coronavirus threatens to slow biotechnology startups’ march onto the public markets and constrict a critical source of capital for young drugmakers.

Drug startups for most of the past several years have enjoyed ready access to listing on the Nasdaq, as investors bet heavily on innovations in emerging fields…

Source